Clinical Use
IgG1 monoclonal antibody:
Treatment of locally advanced or metastatic
epidermal growth factor receptor (EGFR) expressing
squamous non-small cell lung cancer
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use.
Metabolism
The elimination routes of necitumumab are only partially
documented, and involve degradation to peptides after
being internalised into its target cells, proteolysis within
the liver or the reticuloendothelial system, as well as
nonspecific endocytosis.
